Board of Directors

Dr. Antonin “Tony” De Fougerolles

Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities towards the market and in helping build several multi-billion dollar companies from start-up stage including Moderna, Alnylam, and Ablynx.

Paul Carter

Paul is a respected leader and board member where he has over the last 25 years held a variety of commercial leadership roles in the biopharmaceutical industry, formally serving as executive vice president, commercial operations of Gilead Sciences. He currently serves on the board of Mallinckrodt Pharmaceuticals PLC and Hutchinson China MediTech Inc.

Martin Andrews

Martin is a respected commercial leader with a strong track record in strategy development and operational delivery most recently as Senior Vice President, Rare Diseases at GlaxoSmithKline, where he oversaw the development and launch of Strimvelis, the world’s first life-saving gene therapy for children. He currently serves on the Board of Freeline Therapeutics.

Evan Caplan

Evan is a Principal on the private investment team at OrbiMed, a leading healthcare investment firm.

Alex Hammacher

Alex is Head of Strategy and Corporate Development at Oxford Science Enterprises, the life science and deep tech investment company based in Oxford. He currently serves on the Board of Vaccitech plc.

Amrit Nagpal

Amrit is a Managing Director, Private Investments at Redmile Group, LLC, a healthcare-focused investment firm based in San Francisco and New York.

Sarah Gordon Wild

Sarah has worked on Wall Street for over 15 years and was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC from 1998 to 2003. She is also currently on the board of Oxford Nanopore and Redx.

Kevin Raidy

Kevin Raidy is the Managing Partner of Cowen Healthcare Investments. He is currently a member of the Board of Directors for several biotechnology companies including Aro Biotherapeutics and Orchard Therapeutics.

Vidu Shanmugarajah

Vidu is a partner on the investing team at GV, based in London. He is also GV’s legal counsel for Europe. Before joining GV in 2015, Vidu’s career spanned law, startups, and investing.

Professor Matthew Wood

Matthew is Professor of Neuroscience and Deputy Head of the Medical Sciences Division at Oxford University and directs the Laboratory of RNA Biology and Neuromuscular Disease.